Monoclonal antibodies in the treatment of ovarian cancer

Monoclonal antibody application in ovarian cancer started eight years after the discovery of Köhler and Milstein, with the studies of Bast et al. which led to the introduction of CA 125 antigen estimation to everyday clinical routine. At present, monoclonal antibodies serve as a therapeutic tool for variable targets with the potential to be applied in multiple clinical situations. In the coming decade, the drug market is likely to be flooded with monoclonal antibodies. Most of the available monoclonal antibodies will be produced in bioreactors, using transgenic plants or transgenic animals. Apart from mouse antibodies, chimeric, humanised or human antibodies, oncology will certainly employ chimeric structures with antibody fragments built into the structures of receptors or growth factors. Irrespective of their origin, they will constitute an integral part of medical practice.

Monoclonal antibodies, Ovarian cancer

[1] Kohler G., Milstein C.: "Continuous cultures of fused cells secreting antibody of predefined specifity". Nature, 1975, 495.

[2] Bast R. C. Jr., Klug T . L., St-John E., Jenison E., Niloff J.M., Lazarus H. et al.: "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N. Engl. J. Med., 1983, 13, 309 (15), 883.

[3] Nicodemus Ch. F., Schultes B. C., Hamilton B. L.: "Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies". Expert. Rev. Vaccines, 2002, 1, 35.

[4] Wiseman G. A., White C.A., StabinM., Dunn W. L. eta/.: "Phase I/II 90Y Zevalin TM/90 yttrium ibritumomab tiuxetan. IDEC- 42B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkan's lymphoma". Eur. J. Nucl. Med., 2000, 27 (2), 766.

[5] Hamann P. R., Hinman L. H., Hollander J. et al.: "Gemtuzumab ozogamicin, a potent and selective anti CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia". Bioaconjug. Chem., 2002, 13 (1), 47.

[6] Yip Y. L, Ward R.: "AntiErb B-2 monoclonal antibodies and Erb B-2 directed vaccines". Cancer Immunol. Immunother., 2002, 50, 11, 569.

[7] Epenetos A. A., Hooker G., Krausz T., Snook D., Bodmer W. F.: "Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells". Obstet. Gynecol., 1986, 68 (suppl. 3 }, 71 S.

[8] Courtenay-Luck N. S., Epenetos A. A., Sivolapenko G. B., Larche M., Barkans J. R., Ritter M. A.: "Development of antiidiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies". Lancet, 1988, 15, 2 (8616), 894.

[9] Finkler N. J., Muto M. G., Kassis A. I., Weadock K., Tumeh S. S., Zurawski V. R. Jr, Knapp R. C.: "Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer". Gynecol. Oneal., 1989, 34 (3), 339.

[10] Juweid M., Sharkey R. M., Alavi A., Swayne L. C., Herskovic T., Hanley D. et al.: "Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody".]. Nucl. Med., 1997, 38 (2), 257.

[11] Schmolling J., Reinsberg J., Wagner U., Krebs D.: "Anti-TAG-72 antibody B72.3- immunological and clinical effects in ovanan carcinoma". Hybridoma, 1997, 16 (1), 53.

[12] Muto M. G., Finkler N. J., Kassis A. I., Howes A. E., Anderson L. L., Lau C. C. et al.: "Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125". Gynecol. Oneal., 1992, 45 (3), 265.

[13] Griffin T. W ., Collins J., Bokhari F., Stochl M., Brill A. B., Ito T, et al.: "Intraperitoneal immunoconjugates". Cancer Res., 1990, I, 50 (suppl. 3), 1031 s.

[14] Sweet F., Rosik L. 0., Sommers G. M., Collins J. L.: "Daunorubicin conjugated to a monoclonal anti-CA 125 antibody selectively kills human ovarian cancer cells". Gynecol. Oneal., 1989, 34 (3), 305.

[15] Pai L. H.,B ookman M.A.,O zols R. F.,Yo ung R. C.,S mith J. W. 2"',L ongo D. L. et al.: "Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer". J. Clin. Oneal., 1991, 9 (12), 2095.

[16] Apelgren L. D., Zimmerman D. L.,B riggs S. L., Bumol T. F.: "Antitumor activity of the monoclonal antibody - Vinca alkaloid immunoconjugate LY203725 (KS I /4-4- desacety lvinblastine-3-carboxhydrazine) in a nude mouse model of human ovarian cancer". Cancer Res., 1990, 15, 50 (12), 3540.

[17] Beck E.,H ofmann M.,B ernhardt G., Jager W., Wildt L., Lang N.: "In vitro activity of immunoconjugates between cisplatin and an anti-CA 125 monoclonal antibody on ovarian cancer cell lines". Cell Biophys., 1994, 24, 25163.

[18] Jaime J., Page M.: "Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro". Anticancer Res., 2001, 21 (2A), 1119.

[19] Kosmas C., Epenetos A. A., Courtenay-Luck N. S.: "Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer". Cancer, 1994, 15, 73 (12), 3000.

[20] Baum R. P., Niesen A., Hertel A., Nancy A., Hess H., Donnerstag B. et al.: "Activating anti-idotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma". Cancer, 1994, 1, 73 (suppl. 3), 1121.

[21] Schmolling J., Reinsberg J., Wagner U., Krebs D.: "Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3". Hybridoma, 1995, 14 (2), 183.

[22] Reinartz S., Boerner H., Koehler S., Von Ruecker A., Schlebusch H., Wagner U.: "Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA 125 by determination of intracellular cytokines - a preliminary report". Hybridoma, 1999, 18 (1), 41.

[23] Muto M. G., Finkler N. J., Kassis A. I., Lepisto E. M., Knapp R. C.: "Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125". Gynecol. Oneal., 1990, 38 (2), 244.

[24] Stewart J. S., Hird V., Snook D., Dhokia B., Sivolapenko G., Hooker G. et al.: "Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer". J. Clin. Oneal., 1990, 8 (12), 1941.

[25] Crowther M. E., Ward B. G., Granowska M., Mather S., Britton K. E., Shepherd J. H., Slevin M. L.: " Therapeutic considerationis in the use of intraeritoneal radiolabelled monoclonal antibodies in ovarian carcinoma". Nucl. Med. Commun., 1989, 10 (3), 149.

[26] Bolhuis R. L., Lamers C. H., Goey S. H., Eggermont A. M., Trimbos J. B., Stoter G. et al.: "Adoptive immunotherapy of ovarian carcinoma with bs-Mab-targeted lymphocytes: a multicenter study". Int. J. Cancer Suppl., 1992, 7, 78.

[27] Muto M. G., Finkler N. J., Kassis A. I., Lepisto E. M., Knapp R. C.: "Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125". Gynecol. Oneal., 1990, 38 (2), 244.

[28] Miotti S., Negri D. R., Valota O., Calabrese M., Bolhuis R. L., Gratama J. W. et al.: "Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian carcinoma patients in associated with longer survival". Int. J. Cancer, 1999, 19, 84 (1), 62.

[29] Schultes Ph. D.: "Oral presentation 19th International Advances in the Application of Monoclonal Antibodies in Clinical Oncology" Conference, June 26-28 2002, Vouliagmenti, Greece.

[30] Gordon A.: "20 patient, -chemo-immunotherapy" study of OvaRex®". The annual meeting of the Society of Gynecologic Oncologists (SGO), March 16-20, 2002 in Miami.

[31] Hird V., Maraveyas A., Snook D., Dhokia B., Soutter W. P., Meares C. et al.: "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody". Br. J. Cancer, 1993, 68 (2), 403.